Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770984 | 0.86 | HTT (0.59) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL3760231 | 0.85 | CCR6 (0.57) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL4704081 | 0.85 | CCR6 (0.60) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL2076254 | 0.82 | CCR6 (0.62) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL17872132 | 0.82 | HTT (0.58) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL415520 | 0.81 | CCR6 (0.64) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL2076561 | 0.81 | CCR6 (0.60) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL19934104 | 0.81 | CCR6 (0.53) | HTTCCR6PAX8SLC1A3SLC1A1 | |
| SCHEMBL417675 | 0.79 | CCR6 (0.60) | HTTCCR6PAX8CPB1CPB2 | |
| SCHEMBL416941 | 0.79 | CCR6 (0.64) | HTTCCR6PAX8CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216989-B2 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2015-12-22 | — | — | US | disclosed |
| US-20110053967-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | IMBERT THIERRY | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053967-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | NPEPPS, PTMA, PARN | HTT 2186/4885CCR6 2465/4885PAX8 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.